Abstract:Gestational diabetes mellitus (GDM) is a common obstetric complication. Half of women who have GDM will go on to develop type 2 diabetes. Understanding the mechanisms by which this occurs requires an animal model of GDM without ongoing diabetes at conception. C57Bl/6J mice react acutely to a high-fat, high-sucrose (HFHS) challenge. Here, we hypothesized that a periconceptional HFHS challenge will induce glucose intolerance during gestation. C57Bl/6J female mice were placed on an HFHS either 1 or 3 weeks prior … Show more
“…The aim of the present study was to determine whether MI and PB, taken together or separately before and during pregnancy, would impact the development of HFD-induced glucose intolerance during pregnancy (22) . This mouse model allowed a factorial design to determine the interaction of treatments, as well as more thorough examination of potential mechanistic pathways and whole-tissue analysis, which would not be possible in human trials.…”
Section: Discussionmentioning
confidence: 99%
“…They remained on their allocated diet/treatment throughout mating and pregnancy. HFD 1 week prior to and throughout pregnancy has been previously demonstrated to produce an effective mouse model of gestational-specific glucose intolerance (22) . Mice were checked daily by inspection of the vagina for a cervical plug.…”
Section: Experimental Methodsmentioning
confidence: 99%
“…the present study is an adaptation of a mouse model previously developed by Pennington et al (22) . We chose this model because our original model of choice, the heterozygous LepR db/þ mouse, did not display glucose intolerance, as discussed in detail in our previous publications (38,39) .…”
Glucose intolerance during pregnancy – a major driver of gestational diabetes mellitus (GDM) – has significant short- and long-term health consequences for both the mother and child. As GDM prevalence continues to escalate, there is growing need for preventative strategies. There is limited but suggestive evidence that myo-inositol (MI) and probiotics (PB) could improve glucose tolerance during pregnancy. The present study tested the hypothesis that MI and/or PB supplementation would reduce the risk of glucose intolerance during pregnancy. Female C57BL/6 mice were randomised to receive either no treatment, MI, PB (Lactobacillus rhamnosus and Bifidobacterium lactis) or both (MIPB) for 5 weeks. They were then provided with a high-fat diet for 1 week before mating commenced and throughout mating/gestation, while remaining on their respective treatments. An oral glucose tolerance test occurred at gestational day (GD) 16·5 and tissue collection at GD 18·5. Neither MI nor PB, separately or combined, improved glucose tolerance. However, MI and PB both independently increased adipose tissue expression of Ir, Irs1, Akt2 and Pck1, and PB also increased Pparγ. MI was associated with reduced gestational weight gain, whilst PB was associated with increased maternal fasting glucose, total cholesterol and pancreas weight. These results suggest that MI and PB may improve insulin intracellular signalling in adipose tissue but this did not translate to meaningful differences in glucose tolerance. The absence of fasting hyperglycaemia or insulin resistance suggests this is a very mild model of GDM, which may have affected our ability to assess the impact of these nutrients.
“…The aim of the present study was to determine whether MI and PB, taken together or separately before and during pregnancy, would impact the development of HFD-induced glucose intolerance during pregnancy (22) . This mouse model allowed a factorial design to determine the interaction of treatments, as well as more thorough examination of potential mechanistic pathways and whole-tissue analysis, which would not be possible in human trials.…”
Section: Discussionmentioning
confidence: 99%
“…They remained on their allocated diet/treatment throughout mating and pregnancy. HFD 1 week prior to and throughout pregnancy has been previously demonstrated to produce an effective mouse model of gestational-specific glucose intolerance (22) . Mice were checked daily by inspection of the vagina for a cervical plug.…”
Section: Experimental Methodsmentioning
confidence: 99%
“…the present study is an adaptation of a mouse model previously developed by Pennington et al (22) . We chose this model because our original model of choice, the heterozygous LepR db/þ mouse, did not display glucose intolerance, as discussed in detail in our previous publications (38,39) .…”
Glucose intolerance during pregnancy – a major driver of gestational diabetes mellitus (GDM) – has significant short- and long-term health consequences for both the mother and child. As GDM prevalence continues to escalate, there is growing need for preventative strategies. There is limited but suggestive evidence that myo-inositol (MI) and probiotics (PB) could improve glucose tolerance during pregnancy. The present study tested the hypothesis that MI and/or PB supplementation would reduce the risk of glucose intolerance during pregnancy. Female C57BL/6 mice were randomised to receive either no treatment, MI, PB (Lactobacillus rhamnosus and Bifidobacterium lactis) or both (MIPB) for 5 weeks. They were then provided with a high-fat diet for 1 week before mating commenced and throughout mating/gestation, while remaining on their respective treatments. An oral glucose tolerance test occurred at gestational day (GD) 16·5 and tissue collection at GD 18·5. Neither MI nor PB, separately or combined, improved glucose tolerance. However, MI and PB both independently increased adipose tissue expression of Ir, Irs1, Akt2 and Pck1, and PB also increased Pparγ. MI was associated with reduced gestational weight gain, whilst PB was associated with increased maternal fasting glucose, total cholesterol and pancreas weight. These results suggest that MI and PB may improve insulin intracellular signalling in adipose tissue but this did not translate to meaningful differences in glucose tolerance. The absence of fasting hyperglycaemia or insulin resistance suggests this is a very mild model of GDM, which may have affected our ability to assess the impact of these nutrients.
“…Note that, a similar association with CHD was not seen in a different genetic background when exposed to HFD for a shorter period of time (Schulkey et al, ). Studies using STZ, HFD, and high‐fat high‐sucrose diet‐induced rodent models have also been carried out to examine maternal pathologies during late onset of DM during pregnancy or GDM that may affect fetal outcomes (Pasek & Gannon, ; Pennington, van der Walt, Pollock, Talton, & Schulz, ). Additionally, the influence of specific genetic background on the propensity to develop each types of diabetes has also been recognized in mouse models (Leiter, ; Wolf, Lilly, & Shin, ).…”
Section: Rodent Models To Study Mechanisms Associated With Matdmmentioning
Congenital heart disease (CHD) is the most common type of birth defect and is both a significant pediatric and adult health problem, in light of a growing population of survivors. The etiology of CHD has been considered to be multifactorial with genetic and environmental factors playing important roles. The combination of advances in cardiac developmental biology, which have resulted in the elucidation of molecular pathways regulating normal cardiac morphogenesis, and genome sequencing technology have allowed the discovery of numerous genetic contributors of CHD ranging from chromosomal abnormalities to single gene variants. On the other hand, mechanistic details of the contribution of environmental factors to CHD remain unknown. Maternal diabetes mellitus (matDM) is a well-established and increasingly prevalent environmental risk factor for CHD, but the underlying etiologic mechanisms by which pre-gestational matDM increases the vulnerability of embryos to cardiac malformations remains largely elusive. Here, we will briefly discuss the multifactorial etiology of CHD with a focus on the epidemiologic link between matDM and CHD. We will describe the animal models used to study the underlying mechanisms between matDM and CHD and review the numerous cellular and molecular pathways affected by maternal hyperglycemia in the developing heart. Lastly, we discuss how this increased understanding may open the door for the development of novel prevention strategies to reduce the incidence of CHD in this high-risk population.
“…However, the effect of in utero exposure to maternal diabetes on fertility of male offspring has not been studied. We have developed an animal model of gestational glucose intolerance, in which C57BL/6J dams are fed a high fat, high sucrose diet from 1 week pre-gestation through the end of pregnancy 20 . Under this acute HFHS exposure, dams fail to expand beta cell numbers during pregnancy, leading to an inadequate insulin response to glucose challenge, and glucose intolerance during mid-late pregnancy 20 .…”
Obesity affects male fertility and maternal diabetes affects the offspring sperm epigenome. However, the effects of in utero exposure to maternal glucose intolerance in combination with postnatal high fat, high sucrose (HFHS) diet consumption on offspring spermatogenesis is not clear. The present study was designed to test these effects. One week before and during pregnancy, dams were fed either control or HFHS diet to induce gestational glucose intolerance, and returned to standard diet during lactation. Male offspring from each maternal group were split into control and HFHS-fed groups for eight weeks prior to sacrifice at 11, 19 or 31 weeks of age, and reproductive tissues were harvested for analysis of testicular germ cell apoptosis and sperm output. Postnatal HFHS diet suppressed spermatogonia apoptosis in all age groups and maternal HFHS diet reduced testosterone levels at 11 weeks. At 31 weeks of age, the postnatal HFHS diet increased body weight, and reduced epididymis weight and sperm count. The combination of in utero and postnatal exposure impacted sperm counts most significantly. In summary, HFHS diet during pregnancy puts male offspring at greater risk of infertility, particularly when combined with postnatal high fat diet feeding.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.